HEALTHSCMP CHINA
Targeted therapy could turn advanced lung cancer into chronic illness: CUHK study
A Hong Kong co-led global study found that the third-generation targeted therapy lorlatinib kept over half of advanced lung cancer patients alive without disease progression for at least seven years, potentially transforming the disease into a chronic condition. The research was conducted by the Chinese University of Hong Kong.
Mentioned
Related Signal
Adjacent reporting
- Drugs that boost immunity are making lung cancer less deadly
- Science takes on the world’s most lethal malignancy
- Chinese drug reduces lung cancer death risk by 34% in trial
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- Five highlights from lung-cancer research
- Vision problem leads to man's stage 4 lung cancer diagnosis, new drug extends survival